GE HealthCare
(Nasdaq: GEHC)
announced a joint development initiative with Raydiant Oximetry to enhance fetal monitoring capabilities.
The collaboration aims to strengthen the support of clinical decision-making during labor. It leverages the combined expertise and technology of both companies to advance fetal oxygen saturation monitoring technology. They aim to enhance the detection of fetal distress during childbirth.
Raydiant Oximetry develops the Lumerah fetal pulse oximetry technology to improve the detection of fetal distress. The non-invasive, transabdominal fetal pulse oximeter measures the fetal blood oxygen saturation.
This technology has FDA breakthrough device designation and investigational device exemption (IDE). According to a news release, the partnership comes on the heels of the completion of an early feasibility IDE study. It evaluated 30 pregnant women during labor and delivery.
“We are enthusiastic about the potential of our fetal pulse oximetry technology to improve the identification of fetal distress and the opportunity to improve outcomes for mothers and babies during childbirth,” said Dr. Neil P. Ray, founder and CEO of Raydiant Oximetry. “GE HealthCare’s deep knowledge of the fetal monitoring space will help us advance this technology that aims to transform the standard of care in fetal monitoring.”
The companies plan to co-develop solutions through this collaboration. They aim to integrate the Raydiant technology into GE HealthCare’s fetal monitoring and digital perinatal surveillance platforms.
“Together with Raydiant Oximetry, we are proud to be at the forefront of this technology to help clinicians better manage the complexities of perinatal care,” said Larry Boyd, GM, maternal infant care, GE HealthCare. “We are excited about the potential of this technology to complement our current perinatal portfolio and help us enable care that can support every pivotal moment in labor and delivery, for every family and baby.”
